Equity
€1.7m ▲ 11.4%
CYTOMICS CONSULTING paid out €200,000 in dividends. That is 54% of the 2025 profit.
CYTOMICS CONSULTING
Lifetime
6 annual accounts with figures on one time axispeak €827,591 (2021)
€622,830▲ 20.4%
peak €509,487 (2021)
€371,101▲ 3.8%
peak €1.7m (2025)
€1.7m▲ 11.4%
€427,629▲ 3.5%
peak 0 FTE (2022)
-not published
Board2 names since 2020
2 directors and 1 other
Documentsfilings and deeds
14-08-202614 days late
2025abbreviated format
Gross margin from €517,470 to €622,830Dividend €200,000Cash from €212,141 to €100,965
Key points
from the 2025 annual accountsFilings
6 annual accounts 6 late
The 2020 accounts came latest: 31 days after the end of the period.
Position in the sector
€371,101
Higher net result than 90% of companies in education. Sector median €19,449 · 972 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,783 companies had the same profile as CYTOMICS CONSULTING has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,783 companies, not a prediction for CYTOMICS CONSULTING. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 27-01-2020
Director, since 27-01-2020
- 100 sharesdeed of 29-01-2020
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0742547668
Incorporation
Founding capital of €20,000, 100 shares · Founder: · Appointments: (director) and (director) · published on 29-01-2020 · Gazette deed
First establishment
Handekenskruidstraat 11, Ghent
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CYTOMICS CONSULTING Ghent | €2.1m | €0.6m | 79.6% | - |
| Accountants Academy Sint-Martens-Latem | €1.6m | €0.6m | 32.8% | 4.6 |
| DOUBLE PASSNXT Zaventem | €2.4m | €0.6m | 63.7% | - |
| Becra Mol | €1.7m | €1.0m | 51.2% | 3.3 |
| JDL ENERGY Zele | €3.0m | €1.2m | 19.1% | - |
| Chainsource Ghent | €1.1m | €1.0m | 27.6% | - |
| Skilled By Sint-Niklaas | €2.6m | €1.3m | 43.4% | 9.3 |
These companies have the same main activity as CYTOMICS CONSULTING: other education (NACE 85599). They are comparable in size and age: total assets between €1.1m and €3m, founded between 2017 and 2021.
Official details
Source: KBO- Status
- Active since 27-01-2020Normal situation
- Activity
- Other educationNACE 85599and 2 others
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment unit
- 2.300.923.1429041 Ghent, since 27-01-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 25-03-2026
Annual accounts 2025
- ≈ €930,000estimated
- €2.1m▲ 9.7%
- ≈ 0.8 FTEestimated
- Filing
- Filed on 14-08-2026
Insights on CYTOMICS CONSULTING
CYTOMICS CONSULTING files the abbreviated format. That format states no turnover. The gross margin fell from €644,128 in 2020 to €622,830 in 2025.
The balance sheet grew most from 2021 to 2022 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CYTOMICS CONSULTING
- What is the company number of CYTOMICS CONSULTING?
- The company number of CYTOMICS CONSULTING is 0742.547.668. The VAT number is the same number with BE in front: BE 0742.547.668.
- Where is CYTOMICS CONSULTING based?
- The registered office is at Handekenskruidstraat 11, 9041 Ghent.Company details
- What does CYTOMICS CONSULTING do?
- According to the KBO register, the main activity is other education (NACE 85599).
- What is the legal form of CYTOMICS CONSULTING?
- CYTOMICS CONSULTING is a private limited company (BV).
- When was CYTOMICS CONSULTING founded?
- CYTOMICS CONSULTING was founded on 27-01-2020.
- Is CYTOMICS CONSULTING still active?
- Yes, CYTOMICS CONSULTING is an active enterprise in the KBO register.
- Which joint committee does CYTOMICS CONSULTING fall under?
- In its 2025 annual accounts, CYTOMICS CONSULTING states joint committee 330.04 (Health institutions and services).
- What is the turnover of CYTOMICS CONSULTING?
- The turnover in financial year 2025 is ≈ €930,000. This figure is estimated from the gross margin of €622,830 and 37 comparable companies (NACE 85). It probably lies between €670,000 and €1.5m.Financials
- Is CYTOMICS CONSULTING profitable?
- In financial year 2025, CYTOMICS CONSULTING made a profit of €371,101.
- Where can I find the annual accounts of CYTOMICS CONSULTING?
- CYTOMICS CONSULTING filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CYTOMICS CONSULTING due?
- CYTOMICS CONSULTING must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.